Lazard Asset Management
RYTM icon

Lazard Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Lazard Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03M Sell
18,319
-14,569
-44% -$1.32M ﹤0.01% 978
2026
Q1 		$2.86M Buy
32,888
+7,317
+29% +$712K ﹤0.01% 750
2025
Q4 		$2.74M Sell
25,571
-4,668
-15% -$495K ﹤0.01% 744
2025
Q3 		$3.05M Sell
30,239
-69,206
-70% -$6.43M ﹤0.01% 731
2025
Q2 		$6.28M Sell
99,445
-3,757
-4% -$230K 0.01% 672
2025
Q1 		$5.46M Sell
103,202
-3,059
-3% -$170K 0.01% 657
2024
Q4 		$5.95M Buy
+106,261
New +$5.87M 0.01% 593
2024
Q2 		– Sell
-1,733
Closed -$75K – 2401
2024
Q1 		$75K Sell
1,733
-124
-7% -$5.43K ﹤0.01% 1623
2023
Q4 		$85K Buy
+1,857
New +$58.6K ﹤0.01% 1720

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lazard Asset Management's RYTM Position: Q2 2026 in Review

Lazard Asset Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 44% in Q2 2026, selling an estimated $1.32M and leaving 18,319 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Lazard Asset Management first reported a position in RYTM in Q4 2023 and has held it in 9 quarters since. The position peaked at $6.28M in Q2 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Lazard Asset Management held 18,319 shares of Rhythm Pharmaceuticals worth $2.03M as of Q2 2026.
  • Lazard Asset Management sold 14,569 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.32M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #978 holding.
  • Lazard Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • Lazard Asset Management's Rhythm Pharmaceuticals position peaked at $6.28M in Q2 2025.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.